• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MacroGenics, Inc. - Common Stock (NQ:MGNX)

    3.715 +0.025 (+0.68%)
    Streaming Delayed Price Updated: 1:47 PM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about MacroGenics, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    News headline image
    MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations
    TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced... 
    Via MediaOutReach
    Topics Economy
    News headline image
    MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
    • MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million 
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in Upcoming Investor Conferences
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
    FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancer 
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in the Stifel 2025 Healthcare Conference
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics Appoints Eric Risser as President and Chief Executive Officer
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    Synergy CHC (NASDAQ: SNYR) Taps Coca-Cola Exec to Accelerate Global Expansion of “FOCUSfactor®” Energy Drink – More Stocks Moving Inside
    Via AB Newswire
    News headline image
    Power Metallic (TSXV: PNPN) (OTCQB: PNPNF) Positioned for Critical Minerals Breakout Following Acquisition – More Stocks Inside
    Via AB Newswire
    News headline image
    MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics Announces Date of First Quarter 2025 Financial Results
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in Upcoming Investor Conference
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in Upcoming Investor Conferences
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in Upcoming Investor Conference
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics to Participate in Upcoming Investor Conferences
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics Announces Leadership Transition
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
    From MacroGenics, Inc.
    Via GlobeNewswire
    News headline image
    MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
    From TerSera Therapeutics LLC
    Via Business Wire
    News headline image
    MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    MGNX DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action – MGNX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.